No Data
No Data
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 Loss per Share (Vs US$0.97 Loss in 3Q 2023)
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
SAB Biotherapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $6
Unlock the Full List